Chardan Capital Has Bullish Outlook for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at Chardan Capital boosted their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a report released on Wednesday, May 14th. Chardan Capital analyst R. Li now anticipates that the company will post earnings per share of $0.45 for the year, up from their prior forecast of ($1.75). Chardan Capital currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million.

Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald upgraded Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday, May 14th. HC Wainwright cut their target price on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $23.20.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $10.05 on Monday. The business’s fifty day moving average is $8.22 and its 200 day moving average is $9.92. Stoke Therapeutics has a 52-week low of $5.35 and a 52-week high of $17.58. The company has a market capitalization of $548.70 million, a PE ratio of -4.79 and a beta of 1.20.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now directly owns 63,962 shares in the company, valued at $554,550.54. The trade was a 5.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. This represents a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock valued at $143,332 in the last ninety days. 11.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in shares of Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock valued at $36,000 after acquiring an additional 5,084 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Stoke Therapeutics in the fourth quarter worth about $63,000. AlphaQuest LLC purchased a new position in shares of Stoke Therapeutics during the first quarter worth approximately $72,000. US Bancorp DE increased its position in shares of Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after acquiring an additional 11,108 shares during the period. Finally, Fox Run Management L.L.C. purchased a new position in shares of Stoke Therapeutics during the first quarter worth approximately $92,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.